Analysts Set Expectations for Xeris Biopharma Q4 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Investment analysts at Leerink Partnrs lifted their Q4 2025 earnings estimates for Xeris Biopharma in a research report issued to clients and investors on Wednesday, November 12th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings per share of $0.09 for the quarter, up from their prior estimate of $0.07. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share.

XERS has been the topic of several other reports. Leerink Partners raised their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a research report on Tuesday, August 19th. Piper Sandler lifted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $9.58.

Xeris Biopharma Trading Down 0.6%

NASDAQ XERS traded down $0.05 on Friday, hitting $7.22. 377,562 shares of the company traded hands, compared to its average volume of 2,516,457. The business’s 50 day moving average price is $8.36 and its 200-day moving average price is $6.46. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -72.34 and a beta of 0.21. Xeris Biopharma has a 52-week low of $2.82 and a 52-week high of $10.08.

Hedge Funds Weigh In On Xeris Biopharma

A number of large investors have recently added to or reduced their stakes in XERS. AQR Capital Management LLC raised its stake in Xeris Biopharma by 13.4% in the first quarter. AQR Capital Management LLC now owns 946,766 shares of the company’s stock valued at $5,198,000 after buying an additional 111,826 shares during the last quarter. Nuveen LLC acquired a new position in shares of Xeris Biopharma during the first quarter valued at about $12,240,000. New York State Common Retirement Fund raised its position in shares of Xeris Biopharma by 90.3% in the 1st quarter. New York State Common Retirement Fund now owns 43,422 shares of the company’s stock valued at $238,000 after purchasing an additional 20,600 shares during the last quarter. CWM LLC boosted its stake in Xeris Biopharma by 79.3% in the 1st quarter. CWM LLC now owns 66,972 shares of the company’s stock worth $368,000 after purchasing an additional 29,614 shares in the last quarter. Finally, Savvy Advisors Inc. purchased a new stake in Xeris Biopharma during the 2nd quarter worth approximately $189,000. 42.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Xeris Biopharma

In other news, Director Jeffrey W. Sherman sold 42,232 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the sale, the director directly owned 219,188 shares of the company’s stock, valued at approximately $1,735,968.96. The trade was a 16.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Marla Persky sold 15,500 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $7.72, for a total value of $119,660.00. Following the completion of the sale, the director owned 142,000 shares of the company’s stock, valued at $1,096,240. The trade was a 9.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 74,399 shares of company stock worth $577,473 over the last 90 days. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.